Haponiuk-Skwarlińska Julia, Gąsior Jakub S, Albrecht Katarzyna, Łaguna Paweł, Werner Bożena
Department of Pediatric Cardiology and General Pediatrics, Doctoral School, Medical University of Warsaw, Żwirki i Wigury 63 A, Warsaw, 02-091, Poland.
Department of Pediatric Cardiology and General Pediatrics, Medical University of Warsaw, Żwirki i Wigury 63 A, Warsaw, 02-091, Poland.
BMC Pediatr. 2025 May 5;25(1):355. doi: 10.1186/s12887-025-05714-5.
Childhood cancer and its therapy, especially that involving potentially cardiotoxic cancer treatment, can structurally affect muscle strength and heart function, and therefore may result in lowered physical activity (PA). This study protocol aims to find the significant determinants of PA levels in pediatric oncological patients 1-5 years after heart-toxic chemotherapy and/or radiation of the heart region.
The study group will include children 1-5 years after completing cancer therapy involving cardiotoxicity risk factors. The primary outcome of interest is the PA measured with an ActiGraph GT3X Accelerometer for 14 consecutive days and the assessment of WHO pediatric age-adjusted PA norms achievement. Assessed PA levels will be evaluated according to the possible determinants of PA: disease/treatment related risk factors, treatment complications, possible complications after the treatment, cardiac function with echocardiography including 2D and 3D strain imaging, physical function and muscle strength in ALPHA (Assessing Levels of Physical Activity) health-related fitness test battery and exercise capacity in cardiopulmonary exercise testing. The self-efficacy and motivation to PA, quality of life (QoL), lifestyle, socio-demographic, and anthropogenic factors as well as knowledge about the positive impact of PA will be evaluated with original and validated questionnaires. The PA determinants of the study group will be compared to the results of the control group of children in the same follow-up period (> 1 year < 5 years) after completing cancer therapy without cardiotoxic methods.
The results may contribute to the development of future recommendations on prophylactic and therapeutic approaches, as well as proper lifestyle recommendations for children in long-term follow-up after cardiotoxic cancer therapy. The determinants will be used to develop targeted exercise prescriptions and exercise programs.
NCT06256068.
儿童癌症及其治疗，尤其是涉及潜在心脏毒性癌症治疗的情况，会在结构上影响肌肉力量和心脏功能，因此可能导致身体活动（PA）水平降低。本研究方案旨在找出接受心脏毒性化疗和/或心脏区域放疗1至5年后的儿科肿瘤患者PA水平的重要决定因素。
研究组将包括完成涉及心脏毒性风险因素的癌症治疗1至5年的儿童。主要关注的结果是使用ActiGraph GT3X加速度计连续14天测量的PA，以及对世界卫生组织儿童年龄调整后的PA规范达成情况的评估。将根据PA的可能决定因素评估所评估的PA水平：疾病/治疗相关风险因素、治疗并发症、治疗后可能出现的并发症、通过超声心动图评估的心脏功能（包括二维和三维应变成像）、ALPHA（评估身体活动水平）健康相关体能测试电池中的身体功能和肌肉力量，以及心肺运动测试中的运动能力。将使用原始和经过验证的问卷评估PA的自我效能感和动机、生活质量（QoL）、生活方式、社会人口统计学和人为因素，以及关于PA积极影响的知识。研究组的PA决定因素将与完成无心脏毒性方法的癌症治疗后处于相同随访期（>1年<5年）的儿童对照组的结果进行比较。
研究结果可能有助于制定未来关于预防和治疗方法的建议，以及为接受心脏毒性癌症治疗后的儿童长期随访提供适当的生活方式建议。这些决定因素将用于制定有针对性的运动处方和运动计划。
NCT06256068。
